Messages That Motivate: Communicating Alcohol-Related Breast Cancer Risk to Young Adult Women (MEMO)
2 septembre 2026 mis à jour par: Darren Mays, Ohio State University Comprehensive Cancer Center
This is an online cross-sectional experimental survey study examining two cancer communication questions: 1) What features of social media messages communicating the breast cancer risks from alcohol consumption will motivate young adult women to drink less? and 2) Do message features differ in their persuasive effects based on young adult women's alcohol consumption behavior?
Aperçu de l'étude
Statut
Pas encore de recrutement
Les conditions
Description détaillée
This is an online cross-sectional experimental study to examine the effects of features of social media messages in young adult women ages 18-25 who drink alcohol based on valid, self-report outcomes.
Within the survey, participants will be randomized to view messages in one of nine conditions in a 3x3 factorial design with baseline alcohol consumption as a within-participants factor to test the effects of social media message features (content, persuasive themes) on participant responses.
We will also compare the effects of message features for young women who drink within recommended limits (1 drink/day or less on average) and those who exceed recommended drinking limits.
Type d'étude
Interventionnel
Inscription (Estimé)
900
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: The Ohio State University Comprehensive Cancer Center
- Numéro de téléphone: 800-293-5066
- E-mail: OSUCCCClinicaltrials@osumc.edu
Lieux d'étude
-
-
Ohio
-
Columbus, Ohio, États-Unis, 43210
- The Ohio State University Comprehensive Cancer Center
-
Chercheur principal:
- Darren Mays, MPH, PhD
-
Contact:
- Darren Mays, MPH, PhD
- Numéro de téléphone: 614-366-2953
- E-mail: Darren.Mays@osumc.edu
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
Oui
La description
Inclusion Criteria:
- Assigned female at birth
- Age 18-25
- Report drinking alcohol at least once in the past 30 days
- Registered in the United States as a member of the Prolific consumer research platform
- Willing and able to complete procedures in English
Exclusion Criteria:
- Assigned male at birth
- Ages <18 or >25
- Do not report drinking alcohol at least once in the past 30 days
- Not registered in the U.S. as a member of the Prolific consumer research platform
- Not willing or not able to complete procedures
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Arm 1: Risk Only + Industry Deception
|
Risk message content
Messages with information about alcohol industry deception
|
|
Expérimental: Arm 2: Risk Only + YAW Susceptibility
|
Risk message content
Message content with information about why young adult women are susceptible to breast cancer risk from alcohol consumption
|
|
Expérimental: Arm 3: Risk Only + Mechanisms
|
Risk message content
Message content with information about the mechanism by which alcohol contributes to increased breast cancer risk
|
|
Expérimental: Arm 4: Efficacy Only + Industry Deception
|
Messages with information about alcohol industry deception
Efficacy Message Content
|
|
Expérimental: Arm 5: Efficacy Only + YAW Susceptibility
|
Message content with information about why young adult women are susceptible to breast cancer risk from alcohol consumption
Efficacy Message Content
|
|
Expérimental: Arm 6: Efficacy Only + Mechanisms
|
Message content with information about the mechanism by which alcohol contributes to increased breast cancer risk
Efficacy Message Content
|
|
Expérimental: Arm 7: Risk and Efficacy + Industry Deception
|
Risk message content
Messages with information about alcohol industry deception
Efficacy Message Content
|
|
Expérimental: Arm 8: Risk and Efficacy + YAW Susceptibility
|
Risk message content
Message content with information about why young adult women are susceptible to breast cancer risk from alcohol consumption
Efficacy Message Content
|
|
Expérimental: Arm 9: Risk and Efficacy + Mechanisms
|
Risk message content
Message content with information about the mechanism by which alcohol contributes to increased breast cancer risk
Efficacy Message Content
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Message Perceptions
Délai: This assessment is administered immediately after participants view study messages on Day 1
|
We will assess message perceptions using a valid, reliable measure with six questions about whether participants thought the messages were worth remembering, grabbed their attention, and were informative, powerful, convincing, and meaningful. Responses are on a five-point Likert scale from 1 (Strongly disagree) to 5 (Strongly agree). For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean. Higher values are considered a better outcome. |
This assessment is administered immediately after participants view study messages on Day 1
|
|
Effect Perceptions
Délai: This assessment is administered immediately after participants view study messages on Day 1
|
We will capture message effects perceptions using the abbreviated effects perceptions scale.
Items include questions about how much the messages made them feel discouraged to drink alcohol, concerned about drinking alcohol, and made them feel that drinking alcohol is unpleasant on a scale from 1 (Strongly disagree) to 5 (Strongly agree).
For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean.
Higher values are considered a better outcome.
|
This assessment is administered immediately after participants view study messages on Day 1
|
|
Emotional Response
Délai: This assessment is administered immediately after participants view study messages on Day 1
|
We will capture emotional responses to the messages using a valid, four item scale.
Items are "This message made me angry; irritated; aggravated; and annoyed" with responses on a 5-point Likert scale from 1 (Not likely at all) to 5 (Extremely likely).
For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean.
Higher values are considered a better outcome.
|
This assessment is administered immediately after participants view study messages on Day 1
|
|
Counter-arguing
Délai: This assessment is administered immediately after participants view study messages on Day 1
|
We will capture counter-arguing, a measure of whether participants cognitively refute messages, with a valid, three item scale that captures whether participants criticize messages, think of points that go against messages, and are skeptical of the messages.
Responses are on a 5-point Likert scale ranging from 1 (Not at all) to 7 (Very much).
For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean.
Lower values are considered a better outcome.
|
This assessment is administered immediately after participants view study messages on Day 1
|
|
Behavioral Intentions
Délai: This assessment is administered immediately after participants view study messages on Day 1
|
Intentions to reduce alcohol consumption in the future will also be assessed with a valid, multi-item scale capturing whether participants will avoid drinking alcohol completely, reduce the number of occasions when they drink alcohol, and reduce the amount of alcohol they consume on drinking occasions with a 1 (Definitely Will Not) to 4 (Definitely Will) response scale.
For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean.
Higher values are considered a better outcome.
|
This assessment is administered immediately after participants view study messages on Day 1
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Collaborateurs
Les enquêteurs
- Chercheur principal: Darren Mays, MPH, PhD, The Ohio State University Comprehensive Cancer Center
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
1 octobre 2026
Achèvement primaire (Estimé)
30 juin 2028
Achèvement de l'étude (Estimé)
1 juillet 2028
Dates d'inscription aux études
Première soumission
28 août 2026
Première soumission répondant aux critères de contrôle qualité
2 septembre 2026
Première publication (Réel)
3 septembre 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
3 septembre 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
2 septembre 2026
Dernière vérification
1 septembre 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- OSU-26048
- R01CA311193-01 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
OUI
Description du régime IPD
De-identified individual participant data from self-report measures will be deposited in the Inter-university Consortium for Political and Social Research (ICPSR).
ICPSR will make the research data from this project available to the broader social science research community as public-use data files.
These files, in which direct and indirect identifiers have been removed to minimize disclosure risk, may be accessed directly through the ICPSR website.
Délai de partage IPD
The research data from this project will be supplied to ICPSR at the time of publication of the relevant results or at the end of the project period, whichever is sooner, so that any issues surrounding the usability of the data can be resolved.
Delayed dissemination may be possible.
The Delayed Dissemination Policy allows for data to be deposited but not disseminated for an agreed-upon period (typically one year).
Critères d'accès au partage IPD
After agreeing to Terms of Use, users with an ICPSR MyData account and an authorized IP address from a member institution may download the data, and non-members may purchase the files.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .